FDA Seeks Risk-Based Inspection Program

FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.

Related Content:

Regulatory WatchPharmaceutical Technology-11-02-2003

Major Challenges Ahead for FDA and Pharma

FDA Grapples with the Promise and Perils of Gene Therapy

Pandemic Alters Policies and Practices for Drug Development and Regulation